Published
August 23, 2026
Ledisa sells a stick-on wellness patch it marketed as a "GLP-1 Patch," pitched as a needle-free way to get the appetite control people associate with Ozempic. A new California class action alleges the patches contain no GLP-1 at all — only plant extracts like berberine and apple cider vinegar. The case was filed this month, so there is nothing to claim.
Allegations Only · No Settlement Yet
This article describes a class action complaint. The statements below are unproven allegations. Ledisa LLC has not been found liable, there is no certified class, and there is nothing to claim at this time. This page is informational and is not legal advice.
What Is This About?
A proposed class action filed in the U.S. District Court for the Eastern District of California alleges that Ledisa LLC sold adhesive wellness patches under the name "GLP-1 Patches" that contain no GLP-1 and no GLP-1 receptor agonist. The case is captioned Cathey v. Ledisa LLC, No. 1:26-cv-06456-EPG, and was filed on August 13, 2026. Ledisa has not responded in court, has not been found liable, and the allegations remain unproven.The theory is narrow and it is economic, not medical. Nothing in the complaint alleges the patches hurt anyone. The claim is that the product's name and marketing told buyers they were getting the hormone behind Ozempic and Wegovy through their skin, that the patches instead contain plant extracts, and that people paid for something they did not get. The named plaintiff, a Merced, California resident, alleges she bought a pack on Ledisa's website on approximately March 7, 2026 after reading the front label and the site's claims, and that she would not have bought the patches had she known.
Status
Complaint Filed · August 13, 2026
Proposed class action · Cathey v. Ledisa LLC · No. 1:26-cv-06456-EPG (E.D. Cal.)
Allegation
Patches sold as "GLP-1 Patches" allegedly contain no GLP-1 and no GLP-1 receptor agonist
Complaint alleges the ingredients are berberine, apple cider vinegar, cinnamon, pomegranate, resveratrol and folic acid
Who's Covered (Proposed)
U.S. purchasers of Ledisa GLP-1 Patches, plus a California class
No class has been certified · the definitions can still change
Can I Claim?
No — nothing to claim yet
No settlement, no fund, no claim form, no deadline
What Ledisa Sells
Ledisa markets a line of transdermal wellness patches — adhesive stickers worn on the skin — described in the complaint as delivering ingredients through the skin and bypassing digestion. Alongside the GLP-1 Patches, the brand's collection includes Dopamine, Energy, Relax and Sleep patches. According to the complaint, Ledisa began selling the GLP-1 Patches in 2025 through its own website and other online marketplaces including Amazon, in packs of 30.The complaint reproduces the product box: "GLP-1 Patches" in large bold lettering on a teal background, with "Science Backed Formula" underneath. That label is central to the case. The complaint alleges the composition claim sits in the most prominent position on the packaging precisely because it is what moves the product.
The complaint identifies Ledisa LLC as a Delaware limited liability company with its principal place of business in Wilmington, Delaware.
The Marketing the Complaint Points To
The complaint quotes a series of website, packaging and social media claims. Among them: that the patches offer "science-backed GLP-1 support" and "sustained appetite control"; that they "trigger[] GLP-1 release in body" and "keep[] GLP-1 levels steady all day"; and that they offer "a natural approach to weight management…without the need for needles or the digestive upset common with oral tablets." Product-page copy quoted in the filing promises to "Control Your Cravings" and "Transform Your Body," alongside before-and-after imagery.The complaint also points to a "Designed by Experts, Recommended by Doctors" section carrying a "#1 Doctor Approved" badge and physician photographs, and to Instagram posts from April and June 2026 describing a patch that "delivers steady GLP-1 and appetite support through the skin."
The plaintiff's position is that these statements, taken together, tell an ordinary shopper the patch contains the hormone. That is the whole dispute: not whether berberine is a legitimate supplement ingredient, but whether a product named after a hormone it does not contain misleads the person buying it.
Why the Complaint Says a Patch Cannot Work This Way
The filing makes two separate arguments, and it is worth keeping them apart.The first is about contents. The complaint alleges the ingredient list shows berberine, apple cider vinegar, cinnamon, pomegranate, resveratrol and folic acid, and no GLP-1 hormone or receptor agonist of any kind.
The second is about physics, and it would apply even if the patch did contain the drug. The complaint quotes Sheldon Markowitz, M.D., chief of endocrinology at Episcopal Health Services in New York City, telling HealthCentral that effective delivery of GLP-1 by transdermal patch is "not possible" because "these molecules are too large to pass through the skin." C. Michael White, head of the department of pharmacy practice at the University of Connecticut, is quoted saying there are currently no GLP-1 medications that can be absorbed through the skin. Nicholas Messinger, M.D., a clinical pharmacy manager at Mount Sinai Health System, is quoted in the same article saying there are no FDA-approved patches that deliver semaglutide or tirzepatide, and that the only approved formulations are injections and the Wegovy pill.
On the herbal ingredients specifically, the complaint quotes Natasha Bhuyan, M.D., saying none of these supplements has evidence that it can help with weight loss, and noting that many have been studied in oral doses rather than in patch form. It also quotes Alyssa Dominguez, M.D., an endocrinologist at USC's Keck School of Medicine, telling Rolling Stone that the doses in these patches are "super off compared to anything that was in the research studies."
These are the plaintiff's allegations and her selection of published commentary. No court has evaluated any of it, and none of these physicians is a party to the case.
Does the Rename to "Berberine Patches" Matter?
Ledisa has relabeled the product. The complaint alleges the "GLP-1 Patches" name was changed to "Berberine Patches," and that the product is still frequently referred to as GLP-1 Patches online. Retail listings for a Ledisa Berberine Patches box are currently visible on third-party marketplaces.The complaint's position is that the rename does not resolve the deception, because it alleges the same benefit and efficacy claims continue to be made about the same product. Whether that argument holds is exactly the kind of question a defendant tends to raise early, and the court has not addressed it. If you are trying to work out whether you bought the product at issue, the ingredient panel is a more reliable guide than the name on the box.
The Consumer Complaints Quoted in the Filing
The complaint reproduces a sampling of public reviews left on Trustpilot and the Better Business Bureau by people who say they bought the patches, several of which describe the product as false advertising or a scam and report no change in weight or appetite after weeks or months of use.These are quoted in the filing as evidence that the plaintiff's experience was not unusual. They are individual consumer statements, not findings, and Ledisa has not had an opportunity to respond to them in court.
What the Lawsuit Seeks
The complaint brings four counts. Three are California statutory claims pleaded for the California class: the Unfair Competition Law (Cal. Bus. & Prof. Code §§ 17200 et seq.), pleaded under all three of its unfair, fraudulent and unlawful prongs; the False Advertising Law (§§ 17500 et seq.); and the Consumers Legal Remedies Act (Cal. Civ. Code §§ 1750 et seq.). The fourth count, unjust enrichment, is pleaded on behalf of the nationwide class.On the CLRA count the complaint states that counsel sent the required pre-suit notice by certified mail and that, for now, the plaintiff seeks only public injunctive relief on that claim — a procedural step that leaves the door open to damages later if Ledisa does not rectify the alleged violations.
It asks the court to:
• Certify the proposed nationwide and California classes and appoint the plaintiff and her counsel to represent them.
• Declare the challenged conduct unlawful and enjoin it going forward on behalf of the general public.
• Award actual and statutory damages according to proof.
• Order Ledisa to disgorge and make restitution of money obtained through the alleged practices.
• Award pre- and post-judgment interest, attorneys' fees and costs.
The plaintiff is represented by KalielGold PLLC and demands a jury trial. The complaint invokes federal jurisdiction under the Class Action Fairness Act, alleging the putative class members' claims exceed $5 million in the aggregate. Every item above is a request tied to unproven allegations — no money has been awarded, and no court has found any Ledisa statement to be false.
Who Could Be Affected?
The complaint proposes a nationwide class of everyone in the United States who bought Ledisa GLP-1 Patches within the applicable statute of limitations, and a California class of California purchasers over the same period. Ledisa itself, its affiliates, officers, directors and employees and their immediate families, and the presiding judge and chambers staff are excluded.No class has been certified, and the plaintiff expressly reserves the right to add subclasses or amend the definitions as the case develops, so the eventual scope could end up narrower or broader. If you bought the patches, keeping order confirmations, subscription records or card statements is a reasonable precaution. There is nothing to file right now.
Watch for Ledisa Refund Scams
Important: newly filed consumer class actions reliably attract fake "refund" texts, emails and DMs asking you to click a link, confirm card details or pay a small processing fee. There is no Ledisa claim form and no settlement. A real claims process — if one ever exists — would be run by a court-appointed administrator, would be free, and would never ask for banking passwords, gift cards or up-front payments.What Happens Next?
The case is at its earliest stage. Ledisa will have an opportunity to respond, most likely with an answer or a motion to dismiss. Labeling cases like this one frequently draw early challenges to whether a reasonable consumer would actually read the advertising the way the complaint reads it, to whether California statutes can reach a nationwide class, and to what relief remains available to a buyer who now knows what is in the product. If the case survives that stage, the plaintiff would still have to persuade the court to certify a class.Any of that can take months or years, and the case could be narrowed, amended, consolidated, settled or dismissed along the way. OpenClassActions.com will update this page if a motion to dismiss is decided, a class is certified, or a settlement with an actual claim form is announced.
Questions
What does the Ledisa GLP-1 patch lawsuit allege?
The complaint alleges that Ledisa LLC sold transdermal patches labeled GLP-1 Patches that contain no GLP-1 hormone and no GLP-1 receptor agonist, and that the herbal ingredients they do contain cannot deliver the advertised appetite control and weight management benefits through the skin. It brings claims under California's Unfair Competition Law, False Advertising Law and Consumers Legal Remedies Act, plus unjust enrichment on behalf of a nationwide class. Ledisa has not been found liable and the allegations are unproven.
Is there a Ledisa settlement or money to claim right now?
No. This is a newly filed complaint. There is no settlement, no settlement fund, no certified class and no claim form. Anyone asking you to pay a fee to file a Ledisa claim today is running a scam. A real claims process, if one is ever created, would be run by a court-appointed administrator and would be free.
Do the Ledisa patches contain GLP-1?
According to the complaint, no. It alleges the ingredient list shows plant extracts such as berberine, apple cider vinegar, cinnamon, pomegranate, resveratrol and folic acid, with no GLP-1 hormone and no GLP-1 receptor agonist such as semaglutide or tirzepatide. That is the plaintiff's allegation; Ledisa has not yet responded in court.
Can GLP-1 medication be delivered through a skin patch?
Physicians quoted in the complaint say no. An endocrinologist told HealthCentral that GLP-1 molecules are too large to pass through the skin, and a University of Connecticut pharmacy practice department head said there are currently no GLP-1 medications that can be absorbed that way. The complaint also notes that the only FDA-approved formulations are injections and an oral semaglutide tablet.
Does renaming the product Berberine Patches end the case?
The complaint says it does not. It alleges Ledisa changed the GLP-1 Patches label to Berberine Patches but kept making the same benefit and efficacy claims, and that the product is still referred to as GLP-1 Patches online. Whether the rename affects the claims is a question for the court, which has not ruled on anything yet.
Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
Sources
- Class Action Complaint, Cathey v. Ledisa LLC, No. 1:26-cv-06456-EPG, U.S. District Court, Eastern District of California (filed August 13, 2026)
- HealthCentral — Do GLP-1 Patches Really Work? (source of the Markowitz and Messinger quotes cited in the complaint)
- PBS News — In the gray world of GLP-1 supplements online, health experts urge caution (source of the C. Michael White quote)
- TODAY — Do "GLP-1 Patches" Work for Weight Loss? Doctors Warn About Trend (source of the Dr. Melanie Jay comments)
- Rolling Stone — Influencers Are Hawking "GLP-1 Patches." Do They Work? (source of the Dr. Alyssa Dominguez quote)
- Stanford Medicine News Center — GLP-1s 101: What the science says about weight loss, side effects, safety
- Gallup — In U.S., GLP-1 Usage Reaches New High (cited in the complaint on adoption rates)
For more class actions keep scrolling below.
Status
Complaint Filed — Allegations Unproven
Case Title
Cathey v. Ledisa LLC
Case Number
1:26-cv-06456-EPG
Court
U.S. District Court, Eastern District of California
Date Filed
August 13, 2026
Product
Ledisa GLP-1 Patches
Transdermal wellness patch, 30 per box · later relabeled Berberine Patches · berberine, apple cider vinegar, cinnamon, pomegranate, resveratrol and folic acid
Claims
California UCL, FAL and CLRA · unjust enrichment (nationwide)
